Lazcluze
(Lazertinib)

Lazcluze (lazertinib) is a kinase inhibitor prescribed for use alongside amivantamab as a first-line treatment for adult patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC). This treatment specifically targets patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, offering a new avenue for managing EGFR-positive NSCLC. By inhibiting the growth of cancer cells in patients with these specific mutations, Lazcluze in combination with amivantamab provides a promising therapeutic option, improving treatment outcomes for those battling this aggressive form of lung cancer.

Recommended Dosage: The recommended dosage of Lazertinib is 240 mg taken orally once a day, in combination with amivantamab. Tablets can be administered with or without food, but it’s crucial to swallow the tablets whole—do not crush, split, or chew them. Patients should continue the treatment until either disease progression occurs or unacceptable toxicity is observed. On days when Lazertinib is administered alongside amivantamab, ensure that Lazertinib is taken before amivantamab. 

If a patient misses a dose of Lazertinib but remembers within 12 hours, they should take the missed dose. However, if more than 12 hours have passed, the patient should skip the missed dose and resume the next dose at the regularly scheduled time. In the event of vomiting after taking Lazertinib, patients should not retake the dose but wait until the next scheduled dose.

• Treatment with Lazertinib tablets may increase the risk of venous thromboembolic events such as deep vein thrombosis or pulmonary embolism. Patients taking Lazertinib should be closely monitored for any signs of blood clots, such as leg swelling or shortness of breath. Immediate medical attention is crucial if symptoms appear.
  
• Patients on Lazertinib 80 mg/240 mg tablets may develop Interstitial Lung Disease (ILD) or pneumonitis, which can be life-threatening. Symptoms like difficulty breathing, persistent cough, or fever should prompt immediate discontinuation of Lazertinib and thorough medical evaluation. Early detection and treatment are key for patient safety.
  
• This medicine may cause severe dermatologic adverse reactions, including rash, itching, and peeling skin. Prompt recognition and management of skin reactions are essential. In cases of severe reactions, dose adjustments or discontinuation of therapy may be required to prevent further complications.
  
• Ocular toxicity has been reported with the use of Lazertinib tablets, leading to vision changes, dry eyes, or irritation. Regular eye examinations are recommended during treatment. Patients experiencing sudden or worsening vision problems should consult their healthcare provider for potential adjustments in their treatment.
  
• This therapeutic drug can cause serious harm to a developing fetus. Pregnant women or those planning to become pregnant should avoid using Lazertinib mesylate hydrate tablets. Effective contraception is advised during and for a specified period after treatment to prevent embryo-fetal toxicity. Consultation with a healthcare provider is crucial.
  
• Women taking these tablets are advised not to breastfeed due to the risk of serious adverse effects on the infant. It is unknown if the drug is excreted in human milk, but to avoid potential harm, breastfeeding should be discontinued during treatment and for a period afterward, as recommended by a healthcare provider.
  

What documents are required to import LAZCLUZE to India?

LAZCLUZE (lazertinib) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

LAZCLUZE (lazertinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Lazcluze in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of LAZCLUZE (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Lazcluze 80 mg/240 mg prices in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the LAZCLUZE (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Lazcluze®?

Lazertinib is a Generic Name for the trade name drug Lazcluze®.

What is the Manufacturer’s Name of Lazcluze®?

Lazcluze® is manufactured by Janssen Biotech, Inc.

Is Lazcluze® approved by the FDA?

Yes, Lazcluze® is approved by the FDA. Date of first approval: August 20, 2024.

What is the dosage and form of Lazcluze® supplied?

Lazcluze® is supplied in Tablets of 80 mg and 240 mg for oral administration.

What are the most common side effects of Lazcluze®? 

The most common side effects of Lazcluze® are rash, infusion-related reaction, musculoskeletal pain, nail toxicity, edema, diarrhea, stomatitis, VTE, paresthesia, fatigue, constipation, COVID-19, hemorrhage, dry skin, nausea, decreased appetite, pruritus, and ocular toxicity. 

How much does Lazcluze® 80 mg/240 mg cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on Lazcluze 80 mg/240 mg cost in India, it is recommended that you Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Lazcluze® be available in SAARC countries? 

Apart from Gulf countries, Lazcluze® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the supply of Lazcluze® tablets in these countries, ensuring access to this therapeutic drug through legal and reliable channels.

Is it safe to buy Lazcluze® 80 mg/240 mg tablets online in India?

Yes, one can buy Lazcluze 80 mg/240 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Lazcluze® tablets through legal channels. 

What are the storage conditions of Lazcluze® 80 mg/240 mg tablets?

Tablets should be stored at room temperature, away from moisture and light. Keep lazertinib tablets out of reach of children and do not refrigerate.